The popularity of Sildenafil initially drove a period of growth for pharma, but recent developments present a uncertain picture for shareholders. Lower-cost alternatives are eroding earnings, and ongoing litigation add https://lawsonyunv697843.vblogetin.com/47270423/sildenafil-and-pharma-a-volatile-bet